Recruiting
“A Multicenter, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis with Infusion of Albutein® Combined with Flebogammadif® in Patients with Mild-Moderate Alzheimer’s Disease” (the “Study”), bearing Protocol No. IG 1002 (AMBAR)
Recruiting
Study number: 14863A Protocol title: “Randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Study 3”
Recruiting
Protocol H8A-MC-LZAX “ Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo” (EXPEDITION-3)
Recruiting
ELND005-AG201 “A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients with Moderate to Severe Alzheimer’s Disease”
Recruiting
“A Phase 2, randomized, double-dummy, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-923 (dextromethorphan/quinidine) for the treatment of symptoms of agitation in patient with Alzheimer’s disease”
Recruiting
An open label, multicenter study, evaluating the safety and imaging characteristics of F-AV-1451 in cognitively healthy volunteers, subjects with Mild Cognitive Impairment, and subjects with Alzheimer's disease.
Avid Radiopharmaceuticals
Recruiting
A Randomized, 18-week, placebo-controlled, double-blind, parallel group study of the safety and efficacy of PF-052212377 (SAM-760) in subjects with mild-to-moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
Pfizer Pharmaceuticals
Recruiting
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Eisai Inc.
Recruiting
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Elan Pharma International Limited

Recruiting = Trial is Active and Recruiting